Sionna Therapeutics is trading 5.64% up now at $5.91, primarily as biotech sentiment improves, with XBI up 2.06%.
- The rebound follows the recent collapse triggered by disappointing SION-719 Phase 2a results.
- Sionna halted further development of SION-719 after the trial failed its key activity endpoint.
- No new company-specific announcement was identified for August 25, 2026; investor-law-firm investigations remain an overhang.